Heffernan Michael Thomas
Insider CIK 1448914 · KERX Director · ACTC Director · CRTX Director · COLL Chairman, President and CEO, Director · AKBA Director · SYBX Director · AVTX Director · TRVI Director · BHVN Director · BHVN Director · ENGN Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics, Inc. | M Exercise deriv | 2026-09-15 | 2026-09-17 | 21,052 | — | $0 | 0 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise deriv | 2026-09-15 | 2026-09-17 | 18,421 | — | $0 | 0 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 100 | $15.88 | $1.6K | 6,351 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 20,952 | $15.09 | $316.2K | 6,451 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise | 2026-09-15 | 2026-09-17 | 21,052 | $3.33 | $70.1K | 27,403 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 100 | $15.88 | $1.6K | 6,351 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 18,321 | $15.09 | $276.5K | 6,451 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise | 2026-09-15 | 2026-09-17 | 18,421 | $3.04 | $56.0K | 24,772 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise deriv | 2026-09-15 | 2026-09-17 | 21,052 | — | $0 | 0 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise deriv | 2026-09-15 | 2026-09-17 | 18,421 | — | $0 | 0 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 100 | $15.88 | $1.6K | 6,351 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 20,952 | $15.09 | $316.2K | 6,451 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise | 2026-09-15 | 2026-09-17 | 21,052 | $3.33 | $70.1K | 27,403 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 100 | $15.88 | $1.6K | 6,351 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | S Sale | 2026-09-15 | 2026-09-17 | 18,321 | $15.09 | $276.5K | 6,451 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | M Exercise | 2026-09-15 | 2026-09-17 | 18,421 | $3.04 | $56.0K | 24,772 | SEC↗ |
| ENGN enGene Therapeutics Inc. | A Award deriv | 2026-06-16 | 2026-06-17 | 31,000 | — | $0 | 31,000 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2026-06-03 | 2026-06-04 | 35,000 | — | $0 | 35,000 | SEC↗ |
| AVTX Avalo Therapeutics, Inc. | A Award deriv | 2026-06-02 | 2026-06-04 | 29,500 | — | $0 | 29,500 | SEC↗ |
| BHVN Biohaven Ltd. | A Award deriv | 2026-04-28 | 2026-04-30 | 68,693 | — | $0 | 68,693 | SEC↗ |
| ENGN enGene Holdings Inc. | A Award deriv | 2025-07-08 | 2025-07-10 | 45,000 | — | $0 | 45,000 | SEC↗ |
| AVTX Avalo Therapeutics, Inc. | A Award deriv | 2025-06-17 | 2025-06-18 | 29,500 | — | $0 | 29,500 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2025-06-11 | 2025-06-13 | 45,000 | — | $0 | 45,000 | SEC↗ |
| BHVN Biohaven Ltd. | A Award deriv | 2025-05-05 | 2025-05-07 | 31,716 | — | $0 | 31,716 | SEC↗ |
| AVTX Avalo Therapeutics, Inc. | A Award deriv | 2025-03-25 | 2025-03-26 | 50,000 | — | $0 | 50,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2025-02-10 | 2025-02-12 | 4,820 | — | $0 | 50,328 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2024-06-13 | 2024-06-14 | 30,000 | — | $0 | 30,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2024-05-16 | 2024-05-16 | 7,693 | — | $0 | 45,508 | SEC↗ |
| BHVN Biohaven Ltd. | A Award deriv | 2024-04-30 | 2024-05-02 | 16,592 | — | $0 | 16,592 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2023-06-28 | 2023-06-30 | 30,000 | — | $0 | 30,000 | SEC↗ |
| SYBX SYNLOGIC, INC. | A Award deriv | 2023-06-22 | 2023-06-26 | 30,000 | — | $0 | 30,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2023-05-18 | 2023-05-19 | 9,792 | — | $0 | 37,815 | SEC↗ |
| BHVN Biohaven Ltd. | A Award deriv | 2023-05-02 | 2023-05-04 | 52,906 | — | $0 | 52,906 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-27 | 2022-12-27 | 15,995 | — | $0 | 3,820 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-27 | 2022-12-27 | 3,820 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-27 | 2022-12-27 | 3,820 | $24.16 | $92.3K | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-27 | 2022-12-27 | 3,820 | $16.15 | $61.7K | 31,843 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-27 | 2022-12-27 | 15,995 | $23.63 | $378.0K | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-27 | 2022-12-27 | 15,995 | $16.15 | $258.3K | 44,018 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-23 | 2022-12-27 | 4,989 | — | $0 | 19,815 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-23 | 2022-12-27 | 4,989 | $23.00 | $114.7K | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-23 | 2022-12-27 | 4,989 | $16.15 | $80.6K | 33,012 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-22 | 2022-12-27 | 237 | — | $0 | 24,804 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-22 | 2022-12-27 | 237 | $16.15 | $3.8K | 28,260 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-22 | 2022-12-27 | 237 | $23.00 | $5.5K | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-21 | 2022-12-21 | 46,600 | — | $0 | 25,041 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-21 | 2022-12-21 | 46,600 | $16.15 | $752.6K | 74,623 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-21 | 2022-12-21 | 46,600 | $23.11 | $1.08M | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-20 | 2022-12-21 | 33,758 | — | $0 | 71,641 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-20 | 2022-12-21 | 33,758 | $23.08 | $779.1K | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-20 | 2022-12-21 | 33,758 | $16.15 | $545.2K | 61,781 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-19 | 2022-12-21 | 3,606 | — | $0 | 105,399 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-19 | 2022-12-21 | 3,606 | $16.15 | $58.2K | 31,629 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-19 | 2022-12-21 | 3,606 | $23.04 | $83.1K | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-13 | 2022-12-14 | 59,524 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-13 | 2022-12-14 | 94,259 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-13 | 2022-12-14 | 7,904 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-13 | 2022-12-14 | 7,904 | $14.57 | $115.2K | 189,710 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-13 | 2022-12-14 | 94,259 | $15.27 | $1.44M | 181,806 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-13 | 2022-12-14 | 59,524 | $14.90 | $886.9K | 87,547 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-13 | 2022-12-14 | 161,687 | $22.16 | $3.58M | 28,023 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-12 | 2022-12-14 | 10,669 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-12 | 2022-12-14 | 15,741 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2022-12-12 | 2022-12-14 | 1,510 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-12 | 2022-12-14 | 1,510 | $14.57 | $22.0K | 55,943 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-12 | 2022-12-14 | 15,741 | $15.27 | $240.4K | 54,433 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2022-12-12 | 2022-12-14 | 10,669 | $14.90 | $159.0K | 38,692 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2022-12-12 | 2022-12-14 | 27,920 | $22.01 | $614.5K | 28,023 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 11,996 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 8,239 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 3,320 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 26,200 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Ltd. | M Exercise deriv | 2022-10-03 | 2022-10-05 | 4,119 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Ltd. | J Other deriv | 2022-10-03 | 2022-10-05 | 13,100 | — | $0 | 13,100 | SEC↗ |
| BHVN Biohaven Ltd. | A Award deriv | 2022-10-03 | 2022-10-05 | 125,000 | — | $0 | 125,000 | SEC↗ |
| BHVN Biohaven Ltd. | M Exercise deriv | 2022-10-03 | 2022-10-05 | 5,998 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Ltd. | M Exercise deriv | 2022-10-03 | 2022-10-05 | 13,100 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Ltd. | J Other deriv | 2022-10-03 | 2022-10-05 | 5,998 | — | $0 | 5,998 | SEC↗ |
| BHVN Biohaven Ltd. | J Other deriv | 2022-10-03 | 2022-10-05 | 4,119 | — | $0 | 4,119 | SEC↗ |
| BHVN Biohaven Ltd. | M Exercise | 2022-10-03 | 2022-10-05 | 13,100 | $2.40 | $31.4K | 24,877 | SEC↗ |
| BHVN Biohaven Ltd. | J Other | 2022-10-03 | 2022-10-05 | 1,660 | — | $0 | 1,660 | SEC↗ |
| BHVN Biohaven Ltd. | M Exercise | 2022-10-03 | 2022-10-05 | 4,119 | $4.84 | $19.9K | 5,779 | SEC↗ |
| BHVN Biohaven Ltd. | F Tax w/h | 2022-10-03 | 2022-10-05 | 5,507 | $7.50 | $41.3K | 19,370 | SEC↗ |
| BHVN Biohaven Ltd. | M Exercise | 2022-10-03 | 2022-10-05 | 5,998 | $3.56 | $21.4K | 11,777 | SEC↗ |
| BHVN Biohaven Ltd. | F Tax w/h | 2022-10-03 | 2022-10-12 | 9,699 | $7.50 | $72.7K | 15,178 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2022-06-23 | 2022-07-01 | 20,000 | — | $0 | 20,000 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2022-06-23 | 2022-06-23 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SYBX SYNLOGIC, INC. | A Award deriv | 2022-06-09 | 2022-06-13 | 27,000 | — | $0 | 27,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2022-05-19 | 2022-05-23 | 14,035 | — | $0 | 28,023 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2022-04-28 | 2022-04-29 | 8,239 | — | $0 | 8,239 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2021-12-20 | 2021-12-22 | 3,320 | — | $0 | 3,320 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2021-06-16 | 2021-06-17 | 20,000 | — | $0 | 20,000 | SEC↗ |
| SYBX SYNLOGIC, INC. | A Award deriv | 2021-06-10 | 2021-06-14 | 15,000 | — | $0 | 15,000 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2021-06-02 | 2021-06-03 | 20,100 | — | $0 | 20,100 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award | 2021-06-02 | 2021-06-03 | 13,700 | — | $0 | 48,586 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2021-05-20 | 2021-05-24 | 9,941 | — | $0 | 13,988 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2021-05-05 | 2021-05-07 | 11,996 | — | $0 | 11,996 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2021-03-15 | 2021-03-17 | 47,044 | $25.26 | $1.19M | 7,078 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2021-03-15 | 2021-03-17 | 3,031 | $25.88 | $78.4K | 4,047 | SEC↗ |
| SYBX SYNLOGIC, INC. | A Award deriv | 2020-12-08 | 2020-12-09 | 30,000 | — | $0 | 30,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2020-08-11 | 2020-08-12 | 13,071 | $19.13 | $250.0K | 54,122 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2020-06-11 | 2020-06-15 | 14,210 | — | $0 | 14,210 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2020-06-05 | 2020-06-09 | 20,100 | — | $0 | 20,100 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award | 2020-06-05 | 2020-06-09 | 13,700 | — | $0 | 34,886 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award deriv | 2020-05-20 | 2020-05-22 | 8,095 | — | $0 | 8,095 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2020-05-20 | 2020-05-22 | 18,650 | $22.05 | $411.2K | 63,146 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2020-05-20 | 2020-05-22 | 4,047 | — | $0 | 67,193 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2020-05-13 | 2020-05-15 | 1,380 | $20.92 | $28.9K | 99,670 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2020-05-13 | 2020-05-15 | 11,969 | $21.21 | $253.9K | 87,701 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2020-05-13 | 2020-05-15 | 5,905 | $22.64 | $133.7K | 81,796 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2020-04-30 | 2021-03-26 | 0 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2020-04-30 | 2020-05-01 | 18,000 | — | $0 | 18,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2020-02-10 | 2020-02-12 | 4,962 | $21.62 | $107.3K | 101,050 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2020-01-31 | 2021-03-26 | 26,200 | — | $0 | 26,200 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2020-01-31 | 2020-01-31 | 36,000 | — | $0 | 36,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2020-01-21 | 2020-01-22 | 275,463 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2020-01-21 | 2020-01-22 | 262,587 | $21.84 | $5.73M | 139,499 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2020-01-21 | 2020-01-22 | 787 | $21.56 | $17.0K | 106,012 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2020-01-21 | 2020-01-22 | 32,700 | $22.69 | $742.0K | 106,799 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2020-01-21 | 2020-01-22 | 275,463 | $5.73 | $1.58M | 402,086 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2019-08-09 | 2019-08-13 | 4,779 | $11.24 | $53.7K | 126,623 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2019-07-19 | 2019-07-23 | 667 | $10.35 | $6.9K | 131,402 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-07-15 | 2019-07-17 | 25,000 | $11.26 | $281.5K | 132,069 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-06-17 | 2019-06-19 | 22,979 | $11.31 | $259.9K | 159,090 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-06-17 | 2019-06-19 | 2,021 | $12.05 | $24.4K | 157,069 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2019-06-06 | 2019-06-10 | 20,100 | — | $0 | 20,100 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award | 2019-06-06 | 2019-06-10 | 13,700 | — | $0 | 21,186 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-05-15 | 2019-05-17 | 18,483 | $12.74 | $235.5K | 188,586 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-05-15 | 2019-05-17 | 6,517 | $13.13 | $85.6K | 182,069 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | C Conversion deriv | 2019-05-09 | 2019-05-13 | 34,247 | — | $0 | 0 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | P Buy | 2019-05-09 | 2019-05-13 | 2,500 | $10.00 | $25.0K | 6,351 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | C Conversion | 2019-05-09 | 2019-05-13 | 3,851 | — | $0 | 3,851 | SEC↗ |
| TRVI Trevi Therapeutics, Inc. | A Award deriv | 2019-05-07 | 2019-05-08 | 23,684 | — | $0 | 23,684 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award deriv | 2019-04-25 | 2019-04-30 | 9,414 | — | $0 | 9,414 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2019-04-25 | 2019-04-30 | 4,707 | — | $0 | 207,069 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-04-15 | 2019-04-17 | 20,192 | $14.91 | $301.1K | 207,170 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-04-15 | 2019-04-17 | 4,808 | $15.87 | $76.3K | 202,362 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-03-15 | 2019-03-19 | 25,000 | $17.17 | $429.3K | 227,362 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-02-15 | 2019-02-20 | 17,932 | $14.71 | $263.8K | 259,430 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-02-15 | 2019-02-20 | 7,068 | $15.06 | $106.4K | 252,362 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2019-02-08 | 2019-02-11 | 7,851 | $14.39 | $113.0K | 277,362 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2019-01-18 | 2019-01-23 | 787 | $15.76 | $12.4K | 285,213 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2019-01-15 | 2019-01-17 | 25,000 | $15.56 | $389.0K | 286,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-12-17 | 2018-12-18 | 3,313 | $18.57 | $61.5K | 311,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-12-17 | 2018-12-18 | 21,687 | $18.12 | $393.0K | 314,313 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | D To issuer deriv | 2018-12-12 | 2018-12-13 | 110,000 | — | $0 | 0 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2018-12-12 | 2018-12-13 | 11,229 | — | $0 | 11,229 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2018-12-12 | 2018-12-13 | 11,229 | — | $0 | 11,229 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2018-12-12 | 2018-12-13 | 18,716 | — | $0 | 18,716 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award deriv | 2018-12-12 | 2018-12-13 | 25,000 | — | $0 | 25,000 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | D To issuer | 2018-12-12 | 2018-12-13 | 20,000 | — | $0 | 0 | SEC↗ |
| AKBA Akebia Therapeutics, Inc. | A Award | 2018-12-12 | 2018-12-13 | 7,486 | — | $0 | 7,486 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-11-15 | 2018-11-16 | 3,600 | $17.05 | $61.4K | 336,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-11-15 | 2018-11-16 | 21,400 | $16.53 | $353.7K | 339,600 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-10-15 | 2018-10-17 | 25,000 | $16.53 | $413.3K | 361,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2018-08-23 | 2018-08-27 | 2,025 | $18.03 | $36.5K | 386,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2018-08-03 | 2018-08-06 | 668 | $20.15 | $13.5K | 388,025 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | A Award deriv | 2018-06-30 | 2018-07-12 | 30,000 | — | $0 | 30,000 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | A Award | 2018-06-30 | 2018-07-12 | 10,000 | — | $0 | 20,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-06-12 | 2018-06-13 | 53,057 | $25.26 | $1.34M | 388,693 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-06-11 | 2018-06-13 | 96,943 | $25.28 | $2.45M | 441,750 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-05-10 | 2018-05-14 | 1,500 | $27.00 | $40.5K | 538,693 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-05-10 | 2018-05-14 | 5,600 | $26.00 | $145.6K | 540,193 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-04-19 | 2018-04-23 | 100 | $26.01 | $2.6K | 545,793 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-04-19 | 2018-04-23 | 44,300 | $26.00 | $1.15M | 545,893 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2018-02-26 | 2018-03-01 | 4,050 | $21.77 | $88.2K | 590,193 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2018-02-05 | 2018-02-06 | 788 | $23.38 | $18.4K | 594,243 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2018-01-26 | 2018-01-29 | 1,044 | $10.17 | $10.6K | 595,031 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award deriv | 2018-01-25 | 2018-01-29 | 150,000 | — | $0 | 150,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2018-01-25 | 2018-01-29 | 75,000 | — | $0 | 593,987 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-01-23 | 2018-01-23 | 16,408 | $25.01 | $410.4K | 518,987 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-01-22 | 2018-01-23 | 3,592 | $25.00 | $89.8K | 535,395 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2018-01-19 | 2018-01-19 | 20,000 | $22.50 | $450.0K | 538,987 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | S Sale | 2017-11-15 | 2017-11-17 | 50,000 | $15.53 | $776.5K | 558,987 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2017-08-04 | 2017-08-04 | 736 | $12.39 | $9.1K | 608,987 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2017-07-28 | 2017-08-04 | 640 | $10.60 | $6.8K | 609,723 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | A Award deriv | 2017-06-09 | 2017-06-20 | 30,000 | — | $0 | 30,000 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | A Award | 2017-06-09 | 2017-06-20 | 10,000 | — | $0 | 10,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | F Tax w/h | 2017-03-17 | 2017-03-21 | 1,472 | $14.95 | $22.0K | 609,083 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award deriv | 2017-02-10 | 2017-02-14 | 110,000 | — | $0 | 110,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2017-02-10 | 2017-02-14 | 55,000 | — | $0 | 610,555 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2017-01-31 | 2017-02-02 | 3,013 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2017-01-31 | 2017-02-02 | 3,013 | $0.48 | $1.4K | 555,555 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2017-01-27 | 2017-02-02 | 1,239 | $10.08 | $12.5K | 552,542 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2016-07-29 | 2016-08-03 | 1,212 | $10.31 | $12.5K | 551,303 | SEC↗ |
| KERX KERYX BIOPHARMACEUTICALS I | A Award deriv | 2016-06-21 | 2016-06-23 | 50,000 | — | $0 | 50,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2016-04-05 | 2016-04-07 | 3,931 | — | $0 | 3,013 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise deriv | 2016-04-05 | 2016-04-07 | 9,673 | — | $0 | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2016-04-05 | 2016-04-07 | 9,673 | $3.31 | $32.0K | 383,117 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | M Exercise | 2016-04-05 | 2016-04-07 | 3,931 | $0.48 | $1.9K | 387,048 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 100,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 10,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 1,250 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 10,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 5,000 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | D To issuer deriv | 2016-02-10 | 2016-02-11 | 3,621 | — | $0 | 0 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | U Tender | 2016-02-10 | 2016-02-11 | 31,000 | $8.50 | $263.5K | 0 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award deriv | 2016-01-20 | 2016-01-22 | 109,005 | — | $0 | 109,005 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award | 2016-01-20 | 2016-01-22 | 18,135 | — | $0 | 373,444 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award deriv | 2016-01-04 | 2016-01-04 | 10,000 | — | $0 | 10,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-12-31 | 2016-01-04 | 2,500 | — | $0 | 31,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-09-30 | 2015-10-01 | 2,500 | — | $0 | 28,500 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-06-30 | 2015-07-02 | 2,500 | — | $0 | 26,000 | SEC↗ |
| COLL COLLEGIUM PHARMACEUTICAL, | A Award deriv | 2015-05-14 | 2015-05-18 | 70,193 | — | $0 | 70,193 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2015-03-31 | 2015-04-01 | 2,500 | — | $0 | 23,500 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award deriv | 2015-01-02 | 2015-01-05 | 10,000 | — | $0 | 10,000 | SEC↗ |
| OCAT Ocata Therapeutics, Inc. | A Award | 2014-12-31 | 2015-01-02 | 2,500 | — | $0 | 21,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2014-09-30 | 2014-10-01 | 2,500 | — | $0 | 18,500 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2014-09-25 | 2014-09-26 | 100,000 | — | $0 | 100,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2014-06-30 | 2014-07-02 | 250,000 | — | $0 | 1,600,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2014-03-31 | 2014-04-02 | 250,000 | — | $0 | 1,350,000 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 3,571 | $5.60 | $20.0K | 0 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $1.16 | $17.4K | 0 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $4.39 | $65.8K | 0 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $2.35 | $35.3K | 0 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 5,833 | $2.41 | $14.1K | 0 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 10,000 | $3.53 | $35.3K | 0 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | D To issuer deriv | 2014-02-03 | 2014-02-04 | 15,000 | $6.57 | $98.5K | 0 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2014-01-02 | 2014-01-03 | 1,000,000 | — | $0 | 1,000,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-12-31 | 2014-01-03 | 250,000 | — | $0 | 1,100,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2013-11-14 | 2013-11-18 | 125,000 | — | $0 | 125,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2013-11-14 | 2013-11-18 | 125,000 | — | $0 | 125,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-09-30 | 2013-10-02 | 125,000 | — | $0 | 850,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-06-28 | 2013-07-01 | 125,000 | — | $0 | 725,000 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | A Award deriv | 2013-05-22 | 2013-05-23 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2013-03-28 | 2013-04-01 | 125,000 | — | $0 | 600,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2013-01-02 | 2013-02-26 | 500,000 | — | $0 | 500,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-12-31 | 2013-01-04 | 125,000 | — | $0 | 475,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-09-28 | 2012-10-03 | 125,000 | — | $0 | 350,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-06-29 | 2012-07-10 | 125,000 | — | $0 | 225,000 | SEC↗ |
| CRTX CORNERSTONE THERAPEUTICS I | A Award deriv | 2012-05-22 | 2012-05-23 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award deriv | 2012-04-11 | 2012-08-02 | 362,022 | — | $0 | 362,022 | SEC↗ |
| ACTC ADVANCED CELL TECHNOLOGY, | A Award | 2012-04-11 | 2012-04-18 | 100,000 | — | $0 | 100,000 | SEC↗ |